ArticleProceedings of the National Academy of Sciences of the United States of America2011
Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 103 citations in OpenAlex.
- Tiny tools closing the gap: nanobodies in research and therapy.Function (Oxford, England) · 2026Review
- Rapid selection of high-affinity DARPins using click display.Protein engineering, design & selection : PEDS · 2026Article
- A Targeted Integration-Based CHO Cell Platform for Simultaneous Antibody Display and Secretion.Antibodies (Basel, Switzerland) · 2025Article
- Beyond Single Clones: High-Throughput Sequencing in Antibody Discovery.Cold Spring Harbor protocols · 2025Article
- Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining.Nature communications · 2024Article
- Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.Cancer pathogenesis and therapy · 2024Review
- Increased stable integration efficiency in CHO cells through enhanced nuclear localization of Bxb1 serine integrase.BMC biotechnology · 2024Article
- Modular cytosine base editing promotes epigenomic and genomic modifications.Nucleic acids research · 2024Article
- Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects.Frontiers in immunology · 2024Review
- Evolution and synthetic biology.Current opinion in microbiology · 2023Review
- A mammalian cell display platform based on scFab transposition.Antibody therapeutics · 2023Article
- Strategies for enriching and characterizing proteins with inhibitory properties on the yeast surface.Protein engineering, design & selection : PEDS · 2023Article
- Article
- Selection of biophysically favorable antibody variants using a modified Flp-In CHO mammalian display platform.Frontiers in bioengineering and biotechnology · 2023Article
- Simultaneous Maturation of Single Chain Antibody Stability and Affinity by CHO Cell Display.Bioengineering (Basel, Switzerland) · 2022Article
- Lipid Membrane-Based Antigen Presentation to B Cells Using a Fully Synthetic Ex Vivo Germinal Center Model.Advanced nanobiomed research · 2022Article
- Clinical landscape of LAG-3-targeted therapy.Immuno-oncology technology · 2022Review
- Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules.Antibodies (Basel, Switzerland) · 2022Article
- Article
- Engineering Proteins Containing Noncanonical Amino Acids on the Yeast Surface.Methods in molecular biology (Clifton, N.J.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel approach has been developed for the isolation and maturation of human antibodies that replicates key features of the adaptive immune system by coupling in vitro somatic hypermutation (SHM) with mammalian cell display. SHM is dependent on the action of the B cell specific enzyme, activation-induced cytidine deaminase (AID), and can be replicated in non-B cells through expression of recombinant AID. A library of human antibodies, based on germline V-gene segments with recombined human regions was used to isolate low-affinity antibodies to human β nerve growth factor (hβNGF). These antibodies, initially naïve to SHM, were subjected to AID-directed SHM in vitro and selected using the same mammalian cell display system, as illustrated by the maturation of one of the antibodies to low pM K(D). This approach overcomes many of the previous limitations of mammalian cell display, enabling direct selection and maturation of antibodies as full-length, glycosylated IgGs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.